Benzinga | Dec 7, 2021 06:59AM EST

Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Raises Price Target to $23

Oppenheimer analyst Jay Olson maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Perform and raises the price target from $20 to $23.